Q12109 (Q12109): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed an Item)
(‎Changed an Item)
Property / financed by
 
Property / financed by: European Union / rank
 
Normal rank
Property / financed by
 
Property / financed by: Directorate-General for Regional and Urban Policy / rank
 
Normal rank

Revision as of 12:12, 6 February 2020

Project in Czech Republic financed by DG Regio
Language Label Description Also known as
English
No label defined
Project in Czech Republic financed by DG Regio

    Statements

    country
    Czechia
    0 references
    EU contribution
    5,007,500.0 Czech koruna
    0 references
    200,300.0 Euro
    exchange rate to Euro
    0.04 Euro
    point in time
    1 October 2020
    0 references
    budget
    10,015,000.0 Czech koruna
    0 references
    400,600.0 Euro
    exchange rate to Euro
    0.04 Euro
    point in time
    1 October 2020
    0 references
    co-financing rate
    50 percent
    0 references
    expected end time
    30 June 2020
    0 references
    beneficiary name (string)
    VUAB Pharma a.s.
    0 references
    beneficiary
    VUAB Pharma
    0 references
    coordinate location

    50°9'46.91"N, 14°23'2.26"E
    0 references
    postal code
    25263
    0 references
    summary
    Předkládaný projekt je zaměřen na rozšíření výzkumně-vývojového centra pro urychlení a zkvalitnění vývoje konečné lékové formy léčiv nádorových onemocnění, a to jak originálních, tak generických léčiv, které bylo vybudováno v předchozích letech. a. (Czech)
    0 references

    Identifiers

    Czech Kohesio ID
    CZ.01.1.02/0.0/0.0/17_165/0015953
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q12109&oldid=500404"